Pure Global
NCT05827432

FCI Effectiveness in NAFLD Stratification

Field-Cycling Imaging Effectiveness in Non-alcoholic Fatty Liver Disease Stratification
NHS Grampian·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Non-Alcoholic Fatty Liver Disease
Drug/Device/Intervention
Field-cycling imaging (FCI)
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
NHS Grampian
Timeline & enrollment
Phase
N/A
Start date
May 01, 2023
End date
Mar 01, 2024
Enrollment
10 participants
Primary outcome

Differentiation of NAFLD types, from steatosis to liver fibrosis, assessed by Field-Cycling Imaging (FCI) scan

Summary

The goal of this pilot study is exploring whether field-cycling imaging may be able to detect
 characteristics of liver disease in patients with different degree of non-alcoholic fatty
 liver disease (NAFLD) that could be important in reflecting disease progression.

ICD-10 classifications
Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05827432
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05827432 through Pure Global AI's free database. This phase not specified trial is sponsored by NHS Grampian and is currently Not yet recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.